Health Grants for Researchers

National Institutes of Health · Up to $800K

This NIH (NICHD) P50 award funds Intellectual and Developmental Disabilities Research Centers. It is a limited competition: only current recipients of IDDRC P50 awards under RFA-HD-20-016 or RFA-HD-21-009 are eligible to apply, so new applicants do not qualify. Foreign organizations and foreign components are not eligible. A clinical trial is optional, and the stated maximum is about $800,000 for centers running three years.

National Institutes of Health · Amount varies

This NIH (NICHD) P20 exploratory grant funds NExT AI Hubs studying how artificial intelligence technologies affect children diagnosed with or at risk for specific learning disabilities in reading, writing, and mathematics. Foreign organizations and foreign components are not eligible to apply; refer to the NOFO's eligibility section for the full list of eligible domestic applicants. A clinical trial is optional. No specific award amount is stated, and the program emphasizes building research infrastructure and early-career investigators.

National Institutes of Health · Amount varies

This NIH (NIDCD) award funds Clinical Research Center Grants (P50) advancing diagnosis, prevention, and treatment of hearing, balance, smell, taste, voice, speech, or language disorders. Eligible applicants are domestic research-capable organizations, including higher-education institutions, nonprofits, tribal governments, faith-based or community organizations, and U.S. territories; foreign organizations are not eligible to apply, though foreign components may be allowed. A low-risk clinical trial is optional, not required. No dollar range is stated, and applicants should read the NOFO closely and contact NIDCD staff before applying.

National Institutes of Health · Amount varies

This NIH R01 funds research examining the efficacy and clinical effectiveness of digital health technologies for the remote management of type 2 diabetes; a clinical trial is required. Eligible applicants include federal agencies, tribal governments, faith- or community-based organizations, regional organizations, and U.S. territories, in addition to standard research institutions. Foreign organizations and the foreign components of U.S. organizations are not eligible, and foreign components are not allowed. No specific award amount is stated in this record; see the NOFO for full eligibility details.

National Institutes of Health · Amount varies

This NIH (NIDDK) U24 cooperative agreement funds a single Research Coordinating Center to manage data, statistics, and operations for a consortium testing anti-obesity medication strategies in children and adolescents. Clinical trials are not allowed under this center role, and as a cooperative agreement NIH staff are substantially involved; this is a specialized coordinating-center award rather than a broad research grant. Foreign organizations, the foreign components of U.S. organizations, and foreign components are not eligible or allowed. No specific award amount is stated; see the NOFO for full eligibility details.

National Institutes of Health · Up to $1M

This NIH (NIDDK) U01 cooperative agreement funds clinical centers to join a consortium testing anti-obesity medication treatment strategies for children and adolescents with obesity. A clinical trial is required, and as a cooperative agreement NIH staff are substantially involved; applicants are typically clinical research institutions. Foreign organizations, the foreign components of U.S. organizations, and foreign components generally are not eligible or allowed. Stated funding is up to about $1,000,000; consult the NOFO for full eligibility details.

National Institutes of Health · Amount varies

This NIH R01 supports research institutions and investigators studying how to design rigorous clinical trials of rapid-acting psychotropic drugs (RAPIDs) and adjunctive psychosocial interventions. A clinical trial is required, so applicants must be prepared to run one. Foreign (non-U.S.) organizations, foreign components of U.S. organizations, and foreign components generally are not eligible or allowed. The notice does not state an award ceiling; refer to the NOFO for eligibility and budget details.

National Institutes of Health · Amount varies

This NIH (NCI) UH2/UH3 award funds both analytical and clinical validation of molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Eligible applicants include higher-education institutions, nonprofits, tribal governments, and federal agencies; clinical trials are not allowed and applicants should already have assays that work on human samples. Foreign organizations and the foreign components of U.S. organizations are not eligible to apply, though some foreign components are allowed. No specific award amount is stated in this record.

National Institutes of Health · Up to $250K

This NIH (NCI) UH3 award funds the clinical validation of already analytically validated molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response, using specimens from clinical trials or studies. Eligible applicants include higher-education institutions, nonprofits, tribal governments, and federal agencies; clinical trials are not allowed and early-stage technology development is out of scope. Applicants must already have an analytically validated assay, which narrows who can realistically apply. Foreign organizations and foreign components of U.S. organizations are not eligible to apply; stated funding is around $250,000.

National Institutes of Health · Amount varies

This NIH (NCI) award funds revision applications to clinically validate biomarker assays that were originally developed through existing NIH-supported research grants, meaning applicants generally need an active or prior NCI-supported assay to revise. Eligible applicants include higher-education institutions, nonprofits, tribal governments, and federal agencies; clinical trials are not allowed and early-stage technology development is out of scope. Because it builds on prior NIH funding, eligibility is effectively narrow. No specific award amount is stated in this record.

National Institutes of Health · Amount varies

This NIH (NCI) K99/R00 is a career-transition award for early-stage postdoctoral cancer researchers moving toward independent faculty positions; in this version the candidate may not lead an independent clinical trial (companion NOFOs cover those who will). It is applied for through a host institution such as a university, so eligibility centers on higher-education and research institutions rather than individuals on their own. Foreign institutions and the foreign components of U.S. organizations are not eligible to apply, though some foreign components are allowed. No award ceiling is stated in this record.

National Institutes of Health · Amount varies

This NIH K99/R00 award funds early-stage postdoctoral researchers transitioning to independent, tenure-track faculty positions, with an emphasis on cancer control, prevention, and data science. This specific NOFO is for those planning to lead an independent clinical trial as part of their career development; non-clinical-trial applicants must use a separate companion NOFO. It's aimed at eligible U.S. institutions, and the deadline is October 14, 2026.

National Institutes of Health · Amount varies

This NIH (NICHD) R36 dissertation grant supports individual doctoral candidates completing dissertation research in high-priority child health areas using data from the ECHO Cohort, a de-identified longitudinal dataset of more than 71,000 participants. Because it is a dissertation award, it is narrowly aimed at doctoral students (working through their institutions) in relevant scientific fields, not the general public or organizations broadly. Foreign organizations, the foreign components of U.S. organizations, and foreign components are not eligible or allowed. No specific award amount is stated; see the NOFO for full eligibility details.

National Institutes of Health · Amount varies

This NIH (NIMH) R01 funds research on delivering and improving empirically-supported mental health interventions for older adults living with serious mental illness, conducted in real-world care settings such as primary care, long-term care, and community centers; a clinical trial is optional. Unusually for this batch, foreign (non-U.S.) organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Refer to the NOFO for full eligibility details, as the record points there rather than listing all entity types. No specific award amount is stated.

National Institutes of Health · Up to $300K

This NIH (CounterACT) R01 funds basic research on how chemical warfare agents, toxic industrial chemicals, and pesticides affect the nervous system, aimed at understanding toxicity mechanisms and identifying therapeutic targets. Eligible applicants include higher-education institutions, nonprofits, tribal governments, faith- or community-based organizations, and federal agencies; clinical trials are not allowed. Foreign (non-U.S.) organizations and the foreign components of U.S. organizations are not eligible to apply. The award appears to be roughly $300,000 in stated funding.

National Institutes of Health · $50K–$600K

This NIH (NCI) U24 cooperative agreement funds the continued operation and maintenance of established, widely-adopted informatics tools and resources used across cancer research; clinical trials are optional. Applicants must demonstrate that their resource is already widely used and has had significant impact, so it targets teams maintaining existing informatics infrastructure rather than new projects. Foreign organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Awards range from about $50,000 to $600,000.

National Institutes of Health · Up to $50K

This NIH R03 grant (up to $50,000) is a limited competition open only to current NCATS CTSA Program KL2 scholars and re-entry supplement recipients completing their transition to independent translational science careers. It's not open to researchers outside that specific CTSA cohort. The deadline is October 19, 2026.

National Institutes of Health · $50K–$600K

This NIH (NCI) U24 cooperative agreement funds advanced development and enhancement of emerging cancer informatics technologies that have passed initial prototyping but are not yet widely adopted; clinical trials are optional. It targets teams with a promising informatics tool ready for further development and broader impact, so eligibility is effectively oriented toward established research/informatics groups. Foreign organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Awards range from about $50,000 to $600,000.

National Institutes of Health · Amount varies

This NIH U01 cooperative agreement funds a single Community Engagement Evaluation and Data coordination (CEED) hub to support a community-based participatory research consortium focused on oral health, coordinating data planning, community engagement evaluation, and operational support. Clinical trials are not allowed, and as a cooperative agreement NIH staff are substantially involved. This is a narrow, single-hub coordination role rather than a broad research grant. Foreign organizations, the foreign components of U.S. organizations, and foreign components are not eligible or allowed; see the NOFO for full eligibility details. No award amount is stated.

National Institutes of Health · Amount varies

This NIH/NIMH R34 grant supports pilot research to adapt, optimize, and test behavioral interventions for sleep problems in adolescents and young adults with or at risk for a mental health disorder, and a clinical trial is required. It is a research grant for universities, research institutions, and similar eligible organizations. Foreign (non-U.S.) organizations and foreign components are not eligible. No specific award amounts are listed, and eligibility is oriented toward research institutions rather than nonprofits, businesses, or individuals broadly.